Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Achieves First FDA Nod with REDEMPLO Therapy

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) has achieved a major regulatory milestone as the U.S.Food and Drug Administration approvedREDEMPLO (plozasiran) for the treatment of adult patients with familial chylomicronemia syndrome. This marks the company’s first FDA-approved medicine and represents a pivotal step in its evolution from …

Team Kalkine | 19 November 2025

Global-e Online (NASDAQ:GLBE) Delivers Q3 Beat with Strong GMV and Revenue Growth

Global-e Online Ltd. (NASDAQ:GLBE) a leading direct-to-consumer cross-border e-commerce company, reported a profitable third quarter on Wednesday, marking a significant turnaround from the prior year’s loss. Net profit reached USD 13.18 million, compared to a USD 22.56 million loss during the same period last …

Team Kalkine | 19 November 2025

Stellantis (NASDAQ:STLA) Expands EV Charging Options with Tesla Supercharger Integration

Stellantis (NYSE:STLA) has taken a major step toward improving the electric vehicle ownership experience by announcing the adoption of the North American Charging System for select battery-electric vehicles across North America, Japan, and South Korea. The decision positions Stellantis alongside a growing list of …

Team Kalkine | 19 November 2025

Genmab (NASDAQ:GMAB) Wins Full FDA Clearance for EPKINLY + R2 in Follicular Lymphoma

Genmab A/S (NASDAQ:GMAB) has received a major regulatory milestone with the U.S.Food and Drug Administrationgranting approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide, collectively known as EPKINLY + R2, for adults with relapsed or refractory follicular lymphoma. This approval introduces the first-ever …

Team Kalkine | 19 November 2025

Magna International (NYSE:MGA) Expands China Presence with New Wuhu eDrive Facility

Magna International Inc. (NYSE:MGA), a global mobility technology leader, is increasing its manufacturing presence in China with the launch of a new facility in the Jiujiang Economic Development Zone in Wuhu. The move supports the accelerating shift toward electrification in the world’s largest automotive …

Team Kalkine | 19 November 2025

Freeport-McMoRan (NYSE:FCX) Projects Higher Copper and Gold Output as Grasberg Recovers

Freeport-McMoRan Inc. (NYSE:FCX) announced plans to restore large-scale production at PT Freeport Indonesia’s Grasberg operations in Central Papua beginning in the second quarter of 2026. This move marks a major step in returning one of the world’s most important copper and gold mines to …

Team Kalkine | 19 November 2025

Rothschild Redb Adjusts View on Amazon.com (NASDAQ:AMZN) in Latest Rating

Rothschild Redb downgraded Amazon.com (NASDAQ:AMZN) to a hold rating. The previous stance was strong-buy. The update appeared in a report released on Tuesday. The change was also noted by Zacks.com.

Aditi Sarkar | 19 November 2025

CFM International (NYSE:GE): Riyadh Air Places Firm Order for 120 LEAP-1A Engines

CFM International, a joint venture betweenGE Aerospace (NYSE:GE) and Safran SA (EPA:SAF), has secured a significant new order from Riyadh Air, with the carrier finalizing a firm purchase of 120 LEAP-1A engines. These engines will power the 60 Airbus A321neo aircraft that Riyadh Air …

Team Kalkine | 19 November 2025

Intuit (NASDAQ:INTU) to Launch Personalized Finance Apps Inside ChatGPT Under Multi-Year Deal

Intuit Inc. (NASDAQ:INTU) has revealed a significant multi-year strategic partnership with OpenAI aimed at launching Intuit-powered finance apps directly inside ChatGPT. The announcement marks a key step in Intuit’s broader ambition to integrateartificial intelligenceinto personal and business finance decisions at scale.

Team Kalkine | 19 November 2025

Olema Pharmaceuticals (NASDAQ:OLMA) Climbs 136% on Roche Phase 3 Trial Win

Olema Pharmaceuticals (NASDAQ:OLMA) gained significant market attention after Roche Holding AG (OTC:RHHBY) unveiled promising findings from its phase 3 lidERA trial evaluating giredestrant, an investigational oral selective estrogen receptor degrader, in patients with early-stage ER+/HER2- breast cancer. The large-scale study included more than 4,100 …

Team Kalkine | 19 November 2025